About Derek DiRocco
Derek DiRocco is a director at Acrivon Therapeutics.
Form D filings name Derek DiRocco as a director at Evommune.
Derek DiRocco reports to the SEC as a director of 6 public companies, including Mineralys Therapeutics (MLYS), Evommune (EVMN) and 89bio (ETNB).
Derek DiRocco first appears on SEC filings in 2019.
Experience
This experience comes from SEC filings. The years are when the filings name Derek DiRocco in the role, so the role may have started earlier or lasted longer.
AI
Acrivon Therapeutics, Inc.
Director
2022 – 2026 · Public company (ACRV)
MI
Mineralys Therapeutics, Inc.
Director
2023 – 2026 · Public company (MLYS)
8I
89bio, Inc.
Director
2019 – 2025 · Public company (ETNB)
WI
Werewolf Therapeutics, Inc.
Director
2021 – 2024 · Public company (HOWL)
II
iTeos Therapeutics, Inc.
Director
2020 – 2023 · Public company (ITOS)
Key Colleagues at Startups
The people Derek DiRocco works with at each company, as listed on that company's latest Form D.
Evommune, Inc. · Form D, Jan 8, 2025
JD
Janice Drew
Executive officer
DC
David Cohen
Director
RH
Robert Hopfner
Director
GM
Gregory Moss
Chief Business and Legal Officer
EB
Eugene Bauer
Executive officer and director
FW
Felice Verduyn-van Weegen
Director
FB
Francois Beaubien
Director
JP
Jeegar Patel
Executive officer
YY
Yuexin Yu
Director
BM
Benjamin McGraw
Director
LP
Luis Pena
Executive officer and director
KC
Kyle Carver
Executive officer